Related references
Note: Only part of the references are listed.Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer
Yoshie Kobayashi et al.
SEMINARS IN CANCER BIOLOGY (2020)
Energy metabolism is co-determined by genetic variants in chronic lymphocytic leukemia and influences drug sensitivity
Junyan Lu et al.
HAEMATOLOGICA (2019)
EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia
Subazini Thankaswamy Kosalai et al.
EPIGENETICS (2019)
Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
Xiangfeng Shen et al.
FRONTIERS IN IMMUNOLOGY (2019)
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia
Beatrice Del Papa et al.
CLINICAL CANCER RESEARCH (2019)
A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas
Gouji Toyokawa et al.
ANNALS OF THORACIC SURGERY (2019)
A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL)
Christine I. Chen et al.
LEUKEMIA & LYMPHOMA (2019)
Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia
Elisavet Chartomatsidou et al.
BLOOD ADVANCES (2019)
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway
K. Kondo et al.
LEUKEMIA (2018)
CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia
Hadas Lewinsky et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway
Juan Guo et al.
ONCOTARGET (2017)
MYC regulates the antitumor immune response through CD47 and PD-L1
Stephanie C. Casey et al.
SCIENCE (2016)
The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia
Nikos Papakonstantinou et al.
ONCOTARGET (2016)
PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia
Fabienne McClanahan et al.
BLOOD (2015)
Perturbation of the normal immune system in patients with CLL
Francesco Forconi et al.
BLOOD (2015)
Stromal cell-mediated glycolytic switch in CLL cells involves Notch-c-Myc signaling
Regina Jitschin et al.
BLOOD (2015)
EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity
Junli Yan et al.
BLOOD (2013)
Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal
Mauro Krampera et al.
CYTOTHERAPY (2013)
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia
Davide Brusa et al.
HAEMATOLOGICA (2013)
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2011)
Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells
Carlo Calissano et al.
MOLECULAR MEDICINE (2011)
Myc Enforces Overexpression of EZH2 in Early Prostatic Neoplasia via Transcriptional and Post-transcriptional Mechanisms
Cheryl M. Koh et al.
ONCOTARGET (2011)
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance
Antonina V. Kurtova et al.
BLOOD (2009)
MYC stimulates EZH2 expression by repression of its negative regulator miR-26a
Sandrine Sander et al.
BLOOD (2008)
Mechanisms of disease: Chronic lymphocytic leukemia
N Chiorazzi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
